Antibiotics Market Size & Trends

The global antibiotics market is poised for significant expansion, driven by an increasing demand for effective treatments against infectious diseases. With a projected value of USD 50.91 billion in 2023, the market is expected to grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2030. The rising prevalence of influenza cases, as evident in the over 31 million reported cases in the US during the 2022-2023 flu season, underscores the need for innovative solutions. To address this challenge, market players are investing heavily in the development of advanced products and collaborating on research initiatives. Notably, the COVID-19 pandemic has had a lasting impact on the industry, with many manufacturers leveraging their capacity to produce essential medical supplies during the crisis. As the world continues to navigate the complexities of infectious disease management, the antibiotics market is well-positioned to drive growth and innovation.

                                                 

A recent study by Elsevier Ltd., published in February 2023, sheds light on the intriguing relationship between COVID-19 cases and vaccination patterns regarding global antibiotic sales. The research found that a significant proportion - approximately 75% - of patients with COVID-19 were prescribed antibiotics, which unfortunately contributed to antimicrobial resistance concerns. Notably, sales of all four key antibiotics (cephalosporin, penicillin, macrolides, and tetracycline) gradually returned to pre-pandemic levels by May 2022. Efforts are now being made to develop more advanced products that will bolster the market demand in this sector.

Request for a free sample

https://www.theresearchinsights.com/reports/antibiotics-market-322/request-sample

Market Concentration & Characteristics

The pharmaceutical landscape has witnessed a profound transformation in recent years, characterized by the emergence of novel formulations, combination therapies, and innovative approaches to combating antibiotic resistance. This relentless pursuit of innovation seeks to not only enhance treatment efficacy but also develop strategies to counter evolving bacterial threats. The industry's unwavering investment in research and development serves as a testament to its unrelenting commitment to staying ahead of the curve in infectious disease management.

Several leading pharmaceutical companies, including AbbVie, Inc., copyright Inc., Novartis AG, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd., are actively engaged in merger and acquisition (M&A) activities. By participating in these transactions, these companies can significantly expand their geographic presence and gain entry into new markets, ultimately driving business growth and increased competitiveness.

Drug Class Insights

Penicillin remains the most lucrative segment of the market with a significant revenue share of 23.8% in 2023, underscoring its enduring relevance in treating various infections. As the first discovered antibiotic class, penicillins continue to play a vital role in combating staphylococcal and streptococcal infections, as well as those caused by clostridium and listeria. By either inhibiting cell wall synthesis or preventing peptidoglycan layer formation, these medicines effectively address conditions such as pharyngitis, skin infections, bronchial coughs, gonorrhea, and ear fungus. However, the rising threat of antibiotic resistance, allergic reactions, and other adverse effects is expected to compromise their market share over the forecast period. A recent WHO article highlights the pressing concern of skin-related neglected tropical diseases (NTDs), which affect approximately 1.8 billion people worldwide at any given time, making this a critical public health issue that requires immediate attention.

Type Insights

The generic antibiotics market made significant strides in 2023, with its revenue share leading the way. Several factors contribute to this dominance, including the affordability of generic formulations, which makes them more accessible to patients. The presence of a diverse range of manufacturers also gives buyers considerable bargaining power, allowing them to negotiate better prices. Moreover, regulatory environments that support generics have played a crucial role in driving market growth. Additionally, government-led initiatives aimed at promoting generic preparations and increasing access to these medications are further fueling the segment's expansion, as they help bridge the gap between essential medicines and affordable treatments.

Action Mechanism Insights

The antibiotics segment that targets cell wall synthesis was a standout performer in 2023, boasting significant market share. By inhibiting bacterial growth with broad-spectrum efficacy against both Gram-positive and Gram-negative organisms, these medicines play a vital role in combating a wide range of infections. As crucial components of the cell wall's structural integrity, their inhibition has a profound impact on cellular function. Cephalosporins, penicillins, carbapenems, and other related agents fall under this category. With research initiatives and government funding ramping up, this segment is poised for substantial growth over the forecast period.

Regional Insights

The Asia Pacific region has solidified its position as the market leader, accounting for 43.8% of the global revenue share in 2023, driven by factors such as the rise in infectious disease cases, widespread non-prescribed medication use, the presence of well-established healthcare infrastructure, and an influx of skilled professionals in the area.

Key Companies & Market Share Insights

Several prominent pharmaceutical companies are vying for dominance in the market, including AbbVie, Inc., Merck & Co., Inc., copyright Inc., and Novartis AG. These industry leaders have established a strong presence through their extensive research and development efforts, innovative product portfolios, and strategic partnerships with other major players.

Key Antibiotics Companies:

• AbbVie, Inc.
• copyright Inc.
• Novartis AG
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals, Inc.
• Viatris, Inc.
• Melinta Therapeutics LLC
• Cipla, Inc.
• Shionogi & Co., Ltd.
• KYORIN Pharmaceutical Co., Ltd.
• GSK Plc
• Nabriva Therapeutics PLC

Recent Developments

• In July 2023, Orchid Pharma, a pharmaceutical company based in India, entered into a technology transfer agreement with a biotechnology company for its fermentation based on the "7ACA" project in the production-linked incentive scheme

• In April 2023, Baxter International Inc. launched ZOSYN in the U.S. (piperacillin and tazobactam) Injection

• In May 2023, Innoviva Specialty Therapeutics got FDA Approval for XACDURO (durlobactam for injection; sulbactam for injection), Co-packaged for Intravenous Use

• In December 2022, the drug application of the new Siderophore Cephalosporin Antibacterial Drug Cefiderocol was accepted for Review in Taiwa

Global Antibiotics Market Report Segmentation

This comprehensive forecast assesses revenue growth across the globe, regional markets, and individual countries, while delving into the most current trends within each segment from 2018 to 2030. By segmenting the market through key categories such as drug class, type, action mechanism, and geographic region, our research provides a detailed analysis of the evolving landscape of antibiotics.

Let's get in touch

The Research Insights Pvt. Ltd.

Address: 1331 Johnson Dr, Buffalo, Grove, Illinois, Chicago, USA.

Address:The Hub, Lane No. 6, Meera Nagar Garden Society, Meera Nagar, Koregaon Park, Pune, Maharashtra 411001

+91-89564-46619
+1 312-313-8080

+91-89564-46619

[email protected]

#Antibiotics Market Size, #Antibiotics Market Share, #Antibiotics Market, #Antibiotics Market Report Scope